Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

[1]  T. Taxter,et al.  FGFR3-TACC3 fusion in solid tumors: mini review , 2016, Oncotarget.

[2]  M. Ni,et al.  FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling , 2016, Oncogene.

[3]  W. Liang,et al.  Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report , 2016, BMC Cancer.

[4]  M. Lawler,et al.  Overcoming Resistance to Targeted Therapies in Cancer. , 2015, Seminars in oncology.

[5]  P. Stephens,et al.  Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. , 2015, Lung cancer.

[6]  A. Iavarone,et al.  Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.

[7]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[8]  P. Jänne,et al.  Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma , 2014, Clinical Cancer Research.

[9]  Lei Wang,et al.  FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[10]  Yong Soo Choi,et al.  Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[12]  R. Bernards,et al.  Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing , 2013, The Journal of pathology.

[13]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[14]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[15]  M. Nykter,et al.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.

[16]  M. Knowles,et al.  Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.

[17]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[18]  J. Brunet,et al.  Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells , 2012, British Journal of Cancer.

[19]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[20]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[21]  Trista K. Hinz,et al.  Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression , 2010, PloS one.

[22]  D. Haber,et al.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.